Eisai to boost Indian API production to cut costs

Japan's Eisai, which is trying to cut costs worldwide, says it will produce more of its active pharmaceutical ingredients (APIs) at its facilities in India. The company merged two units in India in preparation. It also intends to try to sell more generic drugs. More from FiercePharmaAsia

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.